Nautilus Biotechnology (NAUT) Assets Average (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Assets Average of $170.7 million for Q2 2026, down 7.46% sequentially from $184.4 million in Q1 2026, and down 22.57% YoY from $220.4 million in Q2 2025.
Nautilus Biotechnology (NAUT) Assets Average (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Assets Average for 7 years, with the latest figure at $170.7 million in Q2 2026.
- Quarterly Assets Average fell 22.57% year-over-year to $170.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $170.7 million (down 22.57% YoY) and the FY2025 annual result came in at $216.9 million, down 20.87% from the prior year.
- Assets Average eased to $170.7 million in Q2 2026 per NAUT's latest filing, from $184.4 million in the prior quarter.
- Over five years, Assets Average peaked at $391.6 million in Q1 2022 and troughed at $170.7 million in Q2 2026.
- A 5-year average of $284.5 million and a median of $288.9 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2026: Assets Average jumped 232.52% in 2022, then decreased 22.57% in 2026.
- Over 5 years, Assets Average stood at $354.7 million in 2022, then decreased by 12.05% to $312.0 million in 2023, then decreased by 19.47% to $251.2 million in 2024, then decreased by 21.98% to $196.0 million in 2025, then retreated by 12.93% to $170.7 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $170.7 million, $184.4 million, and $196.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Nautilus Biotechnology | 114.43 Mn | 114.43 Mn | 175,000.00 | 170.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 170.68 Mn |
| Mar 31, 2026 | 184.45 Mn |
| Dec 31, 2025 | 196.01 Mn |
| Sep 30, 2025 | 207.05 Mn |
| Jun 30, 2025 | 220.44 Mn |
| Mar 31, 2025 | 235.22 Mn |
| Dec 31, 2024 | 251.22 Mn |
| Sep 30, 2024 | 266.23 Mn |
| Jun 30, 2024 | 280.70 Mn |
| Mar 31, 2024 | 297.11 Mn |
| Dec 31, 2023 | 311.95 Mn |
| Sep 30, 2023 | 324.55 Mn |
| Jun 30, 2023 | 338.33 Mn |
| Mar 31, 2023 | 347.97 Mn |
| Dec 31, 2022 | 354.68 Mn |
| Sep 30, 2022 | 365.51 Mn |
| Jun 30, 2022 | 378.19 Mn |
| Mar 31, 2022 | 391.56 Mn |
| Dec 31, 2021 | 391.90 Mn |
| Sep 30, 2021 | 389.31 Mn |